At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,333 enrolled
Drug / intervention
inhaled prostacyclin +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso® (Treprostinil) Inhalation Solution
In Brief
An observational study evaluating inhaled prostacyclin, prostacyclin, and 3 other interventions for Pulmonary Arterial Hypertension. Completed, enrolled 1,333 participants across 88 sites.
Detailed Summary
A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Arterial Hypertension
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2010
First PostedDec 2010
Primary CompletionDec 2014
TodayJul 2026
First PostedDec 24, 2010
Enrollment StartDec 1, 2010
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 15.5 years ago
Interventions
inhaled prostacyclindrug
Tyvaso
inhaled prostacyclindrug
As prescribed by the physician
prostacyclindrug
As prescribed by the physician
subcutaneous and intravenous prostacyclindrug
As prescribed by physician
oral ERAdrug
As prescribed by physician
oral PDE5 inhibitorsdrug
As prescribed by physician